Left ventricular hypertrophy: its prime importance as a controllable risk factor

Area of Science:

• Cardiology
• Hypertension Research
• Cardiac Imaging

Background:

• Left ventricular hypertrophy (LVH) is an abnormal increase in left ventricle mass.
• LVH is an independent risk factor for myocardial infarction, heart failure, and sudden death.
• Electrocardiography detects LVH in 5% of hypertensive patients, while echocardiography detects it in 50%.

Purpose of the Study:

• To evaluate the impact of antihypertensive pharmacotherapy on reversing left ventricular hypertrophy.
• To compare the efficacy of different antihypertensive medication classes in reversing LVH.
• To assess potential improvements in cardiac function associated with LVH reversal.

Main Methods:

• Review of studies assessing left ventricular mass changes in hypertensive patients under pharmacotherapy.
• Comparison of echocardiographic data before and after treatment with various antihypertensive agents.
• Analysis of cardiac index, peripheral resistance, and diastolic function parameters.

Main Results:

• Pharmacological control of hypertension can normalize left ventricular mass.
• Diuretics and vasodilators have not shown efficacy in reversing LVH.
• Beta-blockers have demonstrated the ability to reverse LVH over 18–24 months.
• LVH reversal may improve cardiac index, reduce peripheral resistance, and enhance diastolic function.

Conclusions:

• Left ventricular hypertrophy reversal is achievable with specific antihypertensive medications, notably beta-blockers.
• The long-term impact of LVH reversal on reducing cardiac events requires further investigation.
• Certain antihypertensive agents may offer superior long-term cardiovascular risk reduction.